- NAD+ route
- Compounded injection
- Public offer
- Starting at $149
- Listed quantity
- 500 mg total at 200 mg/mL
- Assessment
- U.S.-licensed physician review described
- Regulatory context
- 2026 FDA letter concerns GLP-1 marketing, not an NAD+ test result
The useful detail on the listing
Strut Health lists compounded NAD+ injection in its wellness and longevity catalog. The public offer specifies a starting price of $149 alongside 500 mg and a concentration of 200 mg/mL. Showing both total amount and concentration makes the container easier to describe than a price-only listing. It still does not establish how long any individual's prescription will last or what their total care will cost.
We keep this offer in the injection category. Strut's broader catalog also contains sermorelin products, but those are different compounds and should not become interchangeable entries in an NAD+ comparison.
What to verify about payment
A starting price should be tied to a specific order before it enters a budget. Ask whether the quoted $149 is the full medication charge for the container shown, what refill arrangement applies, and whether there are any separately payable clinical or delivery services. A daily-price illustration is not sufficient evidence of the actual recurring invoice.
Also ask what happens when a prescription changes before the next shipment. A plan can have a simple advertised price while the timing of a refill remains material. Saving the checkout terms gives the patient a clearer reference than a marketing tile alone.
Keep the biology accurate
The NAD+ product page includes a tile describing a peptide that signals the pituitary gland. That description does not correctly describe NAD+, which is a coenzyme. It resembles language associated with a different product category. Readers should ask the prescriber to identify the actual intended preparation and should not infer hormone-related effects from that tile.
This inconsistency affects how we read the page, but it is not laboratory evidence about the contents of a dispensed vial. Our review separates the accuracy of website explanations from questions about manufacturing, clinical suitability and product performance.
The FDA letter in its proper scope
FDA issued a warning letter to Strut Health on February 20, 2026 concerning representations about compounded semaglutide and tirzepatide, including who compounded them and implications about approval. That is relevant background about the provider's marketing. The letter is not a finding that Strut's NAD+ product was contaminated or that an NAD+ batch failed testing.
A reader can review the letter directly and ask the company about the changes it made. We do not infer current resolution from the storefront remaining online, and we do not extend the letter's specific allegations to unrelated products.
The comparison that remains useful
Strut supplies enough quantity information to support a concrete consultation question: what exactly is included at the quoted price for the listed container? That is a better starting point than a numerical quality rating. The next useful answers concern the named pharmacy, shipment arrangements, refill cutoff and a clear point of contact for questions about the prescription.
Evaluate the response on its own terms. Written, product-specific answers can resolve an ambiguous page; repeating broad wellness claims cannot. Anyone seeking help with ongoing fatigue or concentration problems should also discuss an appropriate evaluation rather than treating catalog positioning as a diagnosis.
Useful distinctions
- Public listing includes total quantity and concentration
- Online physician review is described
- Injection offering is separately identifiable
Limitations to weigh
- Starting price is not a verified all-in recurring invoice
- An inaccurate peptide tile requires clarification
- FDA marketing letter should be read in its stated GLP-1 scope
Sources & further reading
Official pages and evidence consulted for this article. Checked October 11, 2026. Provider pages establish advertised terms; they do not independently establish effectiveness.